2020
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
Chow L, Gainor J, Lakhani N, Lee K, Chung H, Lee J, LoRusso P, Bang Y, Hodi F, Santana-Davila R, Fanning P, Squifflet P, Jin F, Wan H, Kuo T, Pons J, Randolph S, Messersmith W. A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. Journal Of Clinical Oncology 2020, 38: 3056-3056. DOI: 10.1200/jco.2020.38.15_suppl.3056.Peer-Reviewed Original ResearchAdverse eventsCheckpoint inhibitorsData cutoffAdvanced malignanciesImmune responseNeck squamous cell cancerCommon being fatigueSquamous cell cancerStandard chemotherapy regimensAdaptive immune responsesHost immune responseAnti-cancer antibodiesCombination cohortAdvanced diseaseChemotherapy regimensGastroesophageal cancerStandard chemotherapyCell cancerPlatinum therapyExcellent tolerabilityHistoric controlsPharmacodynamic markersImmune cellsClinical activityTumor biopsies
2019
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
Chow L, Gainor J, Lakhani N, Chung H, Lee K, Lee J, LoRusso P, Bang Y, Hodi F, Fanning P, Zhao Y, Jin F, Wan H, Pons J, Randolph S, Messersmith W. A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. Journal Of Clinical Oncology 2019, 37: 2514-2514. DOI: 10.1200/jco.2019.37.15_suppl.2514.Peer-Reviewed Original ResearchCheckpoint inhibitorsImmune responseNon-small cell lung cancerPK/PD characteristicsNeck squamous cell carcinomaGastroesophageal junction cancerCell lung cancerSquamous cell carcinomaHost immune responseData cutoffAdvanced malignanciesAdverse eventsJunction cancerObjective responseRefractory diseaseTumor histologyExcellent tolerabilityCell carcinomaPharmacodynamic markersLung cancerImmune cellsAnticancer antibodiesAST increasePatientsALT increase